Ashley A. Lemnios

This study develops ALD-coated microparticles for vaccines that enable controlled antigen release and enhance immune responses against HIV.

This study shows that targeting the conserved HIV fusion peptide with modified Env immunogens in rhesus macaques can focus immune responses on neutralizing epitopes.

This paper designs a drug-regulated gene expression system using self-amplifying RNA with TMP-responsive degradation domains, showing enhanced immune responses in mice.

The paper investigates how vaccine antigen delivery and adjuvant selection affect the priming of rare HIV broadly neutralizing antibody-precursor B cells in non-human primates, finding that specific dosing and adjuvant combinations enhance their detection in germinal centers.

This study evaluates the dose-dependent effects of the SMNP adjuvant on HIV Env-specific immune responses in non-human primates, showing increased memory T and B cell responses and neutralizing antibodies at higher doses.

This paper describes an engineered SARS-CoV-2 RBD variant that shows improved immunogenicity in mice and protective immunity in hamsters.